Literature DB >> 12963605

Cataracts and glaucoma in patients with oculocerebrorenal syndrome.

Stacey J Kruger1, M Edward Wilson, Amy K Hutchinson, Mae Millicent Peterseim, Luanna R Bartholomew, Richard A Saunders.   

Abstract

BACKGROUND: Oculocerebrorenal syndrome is an X-linked recessive hereditary oculocerebrorenal disorder characterized by congenital cataract, mental retardation, and Fanconi syndrome of the proximal renal tubules. Other ocular findings include glaucoma, corneal opacity (keloid), enophthalmos, and hypotonia.
OBJECTIVE: To describe the treatment of 7 patients (14 eyes) with bilateral cataracts associated with oculocerebrorenal syndrome. Method Retrospective review.
RESULTS: Seven patients with oculocerebrorenal syndrome had visually significant bilateral cataracts detected on their first full ophthalmic examination. All underwent bilateral cataract surgery. The mean age (of 14 eyes) at cataract extraction was 1.25 (median, 1.1) months. Glaucoma diagnosis and treatment were more variable. The mean age (of 11 eyes) at glaucoma diagnosis was 24.1 (range, 0.2-70.0) months: the mean age was 0.2 month (of 4 eyes) when glaucoma was diagnosed before cataract extraction, and the mean age was 37.7 months (of 7 eyes) when glaucoma was diagnosed after cataract extraction. All eyes were followed up for a mean of 100.8 (range, 38-190) months. Main Outcome Measure Treatment of 7 patients (14 eyes) with bilateral cataracts associated with oculocerebrorenal syndrome.
CONCLUSIONS: Early identification and surgical removal of cataracts is recommended in patients with oculocerebrorenal syndrome. Despite this, visual acuity results will only rarely be better than 20/70, and nystagmus is likely. Patients should be monitored closely and regularly for changes in intraocular pressure, optic nerve cupping, and refractive error to rule out the development of glaucoma.

Entities:  

Mesh:

Year:  2003        PMID: 12963605     DOI: 10.1001/archopht.121.9.1234

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  Prospective analysis of the predictors of glaucoma following surgery for congenital and infantile cataract.

Authors:  Shantha Balekudaru; Sumita Agarkar; Sujatha Guha; Rishikesh Charudatta Mayee; Natarajan Viswanathan; Amit Pandey; Maneesh Singh; Vijaya Lingam; Ronnie George
Journal:  Eye (Lond)       Date:  2018-12-18       Impact factor: 3.775

2.  OCRL1 mutation in a boy with Dent disease, mild mental retardation, but without cataracts.

Authors:  Vladimir J Lozanovski; N Ristoska-Bojkovska; P Korneti; Z Gucev; V Tasic
Journal:  World J Pediatr       Date:  2011-08-07       Impact factor: 2.764

3.  Clinical and laboratory features of Macedonian children with OCRL mutations.

Authors:  Velibor Tasic; Vladimir J Lozanovski; Petar Korneti; Nadica Ristoska-Bojkovska; Vesna Sabolic-Avramovska; Zoran Gucev; Michael Ludwig
Journal:  Pediatr Nephrol       Date:  2011-01-20       Impact factor: 3.714

4.  Management of cataract surgery in Lowe syndrome.

Authors:  Katharina Eibenberger; Sandra Rezar-Dreindl; Franz Pusch; Ursula Schmidt-Erfurth; Eva Stifter
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

5.  Case Report: Combined Cataract Surgery and Minimally Invasive Glaucoma Surgery Provide an Alternative Treatment Approach for Lowe Syndrome.

Authors:  Chen Wang; Wenzhe Zhang; Leyi Wang; Wenhui Liu; Hui Guo
Journal:  Front Med (Lausanne)       Date:  2022-07-01

Review 6.  The oculocerebrorenal syndrome of Lowe: an update.

Authors:  Arend Bökenkamp; Michael Ludwig
Journal:  Pediatr Nephrol       Date:  2016-03-24       Impact factor: 3.714

Review 7.  How to help children with neurodevelopmental and visual problems: a scoping review.

Authors:  C Williams; K Northstone; C Borwick; M Gainsborough; J Roe; S Howard; S Rogers; J Amos; J M Woodhouse
Journal:  Br J Ophthalmol       Date:  2013-10-24       Impact factor: 4.638

8.  DBA/2J mice are susceptible to diabetic nephropathy and diabetic exacerbation of IOP elevation.

Authors:  Ileana Soto; Gareth R Howell; Cai W John; Joseph L Kief; Richard T Libby; Simon W M John
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.